Beginning of a New Era: Current Progress in Colorectal Cancer Detection, Treatment, and Prognosis

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 June 2024) | Viewed by 4927

Special Issue Editors


E-Mail Website
Guest Editor
Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas, Austin, TX 75063, USA
Interests: medical oncology

E-Mail Website
Co-Guest Editor
1. Department of Medical Education, Dell Medical School, University of Texas at Austin, Austin, TX, USA
2. Department of Oncology, Dell Medical School, University of Texas at Austin, Austin, TX, USA
3. LiveStrong Cancer Institutes, Dell Medical School, University of Texas at Austin, Austin, TX, USA
Interests: pharmacology education; cancer research

Special Issue Information

Dear Colleagues,

Colorectal cancer is one of the most common cancers worldwide, affecting both men and women. Although great advances have been accomplished in the field, with improvement in screening programs, early detection and therapeutic approaches, the mortality remains high. Colorectal cancer is an extremely heterogeneous disease, affecting a diverse patient population. Although the armamentarium of novel treatment modalities and detection tools has grown, providing important improvements in patients selection and outcomes, these new approaches have increased the complexity of treatment algorithms. We now have several different treatment options to offer patients, yet numerous limitations remain. For example, there has been limited progress in the development and clinical use of immunotherapies. Furthermore, there has a pronounced increase in the incidence of early onset colorectal cancer, a disease with many unaddressed needs. Numerous innovations have also emerged in the management of rectal cancer. However, as with colonic cancer, the treatment is complex and defining the most appropriate management is challenging.

In this Special Issue, we will invite experts to support a critical review of the current advancement in the field of colorectal cancer, focusing on recent cutting-edge research and treatment options that may lead to the development of more effective treatments that enhance the survival of patients.

Dr. Anna Capasso
Guest Editor

Dr. Michael William Lee
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colon cancer
  • rectal cancer
  • early onset
  • treatment
  • immunotherapy
  • neoadjuvant
  • metastatic
  • preclinical research
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 5108 KiB  
Article
Association of Serum Proteases and Acute Phase Factors Levels with Survival Outcomes in Patients with Colorectal Cancer
by Tadeusz Sebzda, Jakub Karwacki, Anna Cichoń, Katarzyna Modrzejewska, Jerzy Heimrath, Mirosław Łątka, Jan Gnus and Jakub Gburek
Cancers 2024, 16(13), 2471; https://doi.org/10.3390/cancers16132471 - 6 Jul 2024
Viewed by 943
Abstract
Colorectal cancer (CRC) represents a substantial burden on global healthcare, contributing to significant morbidity and mortality worldwide. Despite advances in screening methodologies, its incidence remains high, necessitating continued efforts in early detection and treatment. Neoplastic invasion and metastasis are primary determinants of CRC [...] Read more.
Colorectal cancer (CRC) represents a substantial burden on global healthcare, contributing to significant morbidity and mortality worldwide. Despite advances in screening methodologies, its incidence remains high, necessitating continued efforts in early detection and treatment. Neoplastic invasion and metastasis are primary determinants of CRC lethality, emphasizing the urgency of understanding underlying mechanisms to develop effective therapeutic strategies. This study aimed to explore the potential of serum biomarkers in predicting survival outcomes in CRC patients, with a focus on cathepsin B (CB), leukocytic elastase (LE), total sialic acid (TSA), lipid-associated sialic acid (LASA), antitrypsin activity (ATA), C-reactive protein (CRP), and cystatin C (CC). We recruited 185 CRC patients and 35 healthy controls, assessing demographic variables, tumor characteristics, and 7 serum biomarker levels, including (1) CB, (2) LE, (3) TSA, (4) LASA, (5) ATA, (6) CRP, and (7) CC. Statistical analyses included ANOVA with Tukey’s post hoc tests and MANOVA for continuous variables. Student’s t-test was used for dependent samples, while non-parametric tests like Mann–Whitney U and Wilcoxon signed-rank tests were applied for variables deviating from the normal distribution. Categorical variables were assessed using chi-square and Kruskal-Wallis tests. Spearman’s rank correlation coefficient was utilized to examine variable correlations. Survival analysis employed the Kaplan–Meier method with a log-rank test for comparing survival times between groups. Significant associations were observed between CB (p = 0.04), LE (p = 0.01), and TSA (p = 0.008) levels and survival outcomes in CRC patients. Dukes’ classification stages also showed a significant correlation with survival (p = 0.001). However, no significant associations were found for LASA, ATA, CRP, and CC. Multivariate analysis of LE, TSA, and ATA demonstrated a notable correlation with survival (p = 0.041), notwithstanding ATA’s lack of significance in univariate analysis (p = 0.13). CB, LE, and TSA emerged as promising diagnostic markers with prognostic value in CRC, potentially aiding in early diagnosis and treatment planning. Further research is needed to validate these findings and explore additional prognostic indicators. Full article
Show Figures

Figure 1

Review

Jump to: Research

17 pages, 841 KiB  
Review
Inflammatory Bowel Disease and Colorectal Cancer
by Jacopo Fanizza, Sarah Bencardino, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese and Ferdinando D’Amico
Cancers 2024, 16(17), 2943; https://doi.org/10.3390/cancers16172943 - 23 Aug 2024
Viewed by 996
Abstract
Patients with inflammatory bowel diseases (IBDs), including both ulcerative colitis (UC) and Crohn’s disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have led to a decrease [...] Read more.
Patients with inflammatory bowel diseases (IBDs), including both ulcerative colitis (UC) and Crohn’s disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have led to a decrease in the incidence of CRC among IBD patients. Currently, the management of patients with IBD who have a history of or ongoing active malignancy is an unmet need. This involves balancing the risk of cancer recurrence/progression with the potential exacerbation of IBD if the medications are discontinued. The objective of this review is to provide an updated summary of the epidemiology, causes, risk factors, and surveillance approaches for CRC in individuals with IBD, and to offer practical guidance on managing IBD patients with history of previous or active cancer. Full article
Show Figures

Figure 1

22 pages, 1020 KiB  
Review
Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine
by Pankaj Ahluwalia, Kalyani Ballur, Tiffanie Leeman, Ashutosh Vashisht, Harmanpreet Singh, Nivin Omar, Ashis K. Mondal, Kumar Vaibhav, Babak Baban and Ravindra Kolhe
Cancers 2024, 16(3), 480; https://doi.org/10.3390/cancers16030480 - 23 Jan 2024
Cited by 6 | Viewed by 2423
Abstract
Colorectal cancer (CRC) is one of the most heterogeneous and deadly diseases, with a global incidence of 1.5 million cases per year. Genomics has revolutionized the clinical management of CRC by enabling comprehensive molecular profiling of cancer. However, a deeper understanding of the [...] Read more.
Colorectal cancer (CRC) is one of the most heterogeneous and deadly diseases, with a global incidence of 1.5 million cases per year. Genomics has revolutionized the clinical management of CRC by enabling comprehensive molecular profiling of cancer. However, a deeper understanding of the molecular factors is needed to identify new prognostic and predictive markers that can assist in designing more effective therapeutic regimens for the improved management of CRC. Recent breakthroughs in single-cell analysis have identified new cell subtypes that play a critical role in tumor progression and could serve as potential therapeutic targets. Spatial analysis of the transcriptome and proteome holds the key to unlocking pathogenic cellular interactions, while liquid biopsy profiling of molecular variables from serum holds great potential for monitoring therapy resistance. Furthermore, gene expression signatures from various pathways have emerged as promising prognostic indicators in colorectal cancer and have the potential to enhance the development of equitable medicine. The advancement of these technologies for identifying new markers, particularly in the domain of predictive and personalized medicine, has the potential to improve the management of patients with CRC. Further investigations utilizing similar methods could uncover molecular subtypes specific to emerging therapies, potentially strengthening the development of personalized medicine for CRC patients. Full article
Show Figures

Graphical abstract

Back to TopTop